Angerer, V, Schmid, Y, Franz, F, Gnann, H, Speer, J, Gnann, A, Helmecke, S, Buchwald, A, Brandt, S, Passie, T, Liechti, M and Auwärter, V (2023) Acute psychotropic, autonomic, and endocrine effects of 5,6-methylenedioxy-2-aminoindane (MDAI) compared with 3,4-methylenedioxymethamphetamine (MDMA) in human volunteers: A self-administration study. Drug Testing and Analysis. ISSN 1942-7603

Passie, T, Adams, HA, Logemann, F, Brandt, SD, Wiese, B and Karst, M (2021) Comparative effects of (S)-ketamine and racemic (R/S)-ketamine on psychopathology, state of consciousness and neurocognitive performance in healthy volunteers. European Neuropsychopharmacology, 44. pp. 92-104. ISSN 0924-977X

Grumann, C, Henkel, K, Brandt, SD, Stratford, A, Passie, T and Auwärter, V (2020) Pharmacokinetics and subjective effects of 1P-LSD in humans after oral and intravenous administration. Drug Testing and Analysis, 12 (8). pp. 1144-1153. ISSN 1942-7603

Brandt, SD, Kavanagh, PV, Westphal, F, Stratford, A, Odland, AU, Klein, AK, Dowling, G, Dempster, NM, Wallach, J, Passie, T and Halberstadt, AL (2020) Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD). Drug Testing and Analysis, 12 (6). pp. 812-826. ISSN 1942-7603

Grumann, C, Henkel, K, Stratford, A, Hermanns-Clausen, M, Passie, T, Brandt, SD and Auwärter, V (2019) Validation of an LC-MS/MS method for the quantitative analysis of 1P-LSD and its tentative metabolite LSD in fortified urine and serum samples including stability tests for 1P-LSD under different storage conditions. Journal of Pharmaceutical and Biomedical Analysis. ISSN 0731-7085